Method of treating rash in patients undergoing anti-EGFR therapy
AssigneeGenmab A/S
InventorsKlaus Edvardsen, Steen Lisby, Ole Baadsgaard
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for the treatment of a disease susceptible to anti-EGFR treatment, comprising the step of administering, to a human being in nee thereof, a combination of an anti-EGFR agent and an anti-neutrophil-chemoattracta agent, wherein said anti-neutrophil-chemoattractant agent is administered in a dosage regimen that is sufficient to reduce one or more undesired dermatological side-effects the anti-EGFR agent. In one embodiment, the anti-EGFR agent is an anti-EGF antibody and the anti-neutrophil-chemoattractant agent is an anti-IL-8 antibody.
Claims34
A method for treating or rash associated with anti-EGFR treatment comprising:
- (a) identifying a subject who is undergoing anti-EGFR treatment and has a rash, wherein said anti-EGFR treatment comprises administering a quinazoline derivative or an antibody capable of binding to EGFR;
- and
- (b) administering, to the subject, an anti-IL8 antibody in an amount sufficient to treat or reduce the rash, wherein the antibody blocks the binding of IL8 to its receptor.
Dependencies are inferred from the claim text.